Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 5:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,231 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: congestive heart failure patients Clear all
Completed Not applicable Interventional

The Effect of Low LEVel TrAgus STimulation on the Electrophysiological Substrate of Patients With Ischemic CardioMyopathy Substrate of Subjects With Ischemic CardioMyopathy

NCT03549468
View directory record Official record
Conditions
Ischemic Cardiomyopathy
Interventions
Low level tragus stimulation
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 90 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 18, 2026, 5:34 AM EDT
Not listed Not applicable Interventional

Community Pharmacy Medication Therapy Management for Heart Failure

NCT03608085
View directory record Official record
Conditions
Heart Failure
Interventions
Pharmacist Heart failure MTM training, Patient Heart failure MTM intervention
Behavioral
Lead sponsor
Providence VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Oct 18, 2026, 5:34 AM EDT
Completed Not applicable Interventional

Cardiac Recovery Through Dietary Support

NCT03759925
View directory record Official record
Conditions
Heart Failure
Interventions
Nutritional Support
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 18, 2026, 5:34 AM EDT
Completed Phase 4 Interventional Results available

Dapagliflozin at Discharge on Hospital Heart Failure Readmission

NCT04249778
View directory record Official record
Conditions
Heart Failure, Diabetes
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 90 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Atlanta, Georgia • New Orleans, Louisiana • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2024 · Synced Oct 18, 2026, 5:34 AM EDT
Enrolling by invitation Not applicable Interventional

Veterans Affairs Pharmacist Heart Failure Medication Titration Project 2

NCT07460219
View directory record Official record
Conditions
Quality Improvement, Pharmacotherapy, Heart Failure
Interventions
Education Only, Education and Feedback (E+F), Primary Care Referral Nudges
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 18, 2026, 5:34 AM EDT
Not listed Not applicable Interventional

Comparing PA Compliance During and After Decompensation in HFP

NCT03914222
View directory record Official record
Conditions
Congestive Heart Failure, Decompensated Heart Failure
Interventions
CardioSpire (Respirix) Device
Device
Lead sponsor
Theranova, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 18, 2026, 5:34 AM EDT
Completed Not applicable Interventional Results available

Monitoring Medication Adherence in Left Ventricular Assist Device Recipients

NCT02388386
View directory record Official record
Conditions
Heart Failure, Medication Compliance
Interventions
PROTEUS-SENSOR
Device
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 18, 2026, 5:34 AM EDT
Not listed No phase listed Observational

The Registry Evaluating Functional Outcomes of Resynchronization Management

NCT00959179
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Not listed
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Elgin, Illinois • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 14, 2009 · Synced Oct 18, 2026, 5:34 AM EDT
Completed Phase 4 Interventional Results available

Digoxin Dosing in Heart Failure: A Simplified Nomogram Versus Standard Care

NCT01005602
View directory record Official record
Conditions
Heart Failure
Interventions
Digoxin Dosing per Nomogram, Digoxin
Other · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
22 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 18, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease

NCT04595370
View directory record Official record
Conditions
Heart Failure, Chronic Kidney Disease
Interventions
AZD9977, Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
21 Years to 130 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
26
States / cities
Beverly Hills, California • Fountain Valley, California • Northridge, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 18, 2026, 5:34 AM EDT
Completed Phase 4 Interventional Results available

Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure

NCT02653482
View directory record Official record
Conditions
Chronic Heart Failure With Reduced Systolic Function
Interventions
Dapagliflozin, Dapagliflozin matching placebo
Drug
Lead sponsor
Saint Luke's Health System
Other
Eligibility
19 Years to 119 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
25
States / cities
Fairhope, Alabama • Los Angeles, California • Jacksonville, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 18, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction

NCT02226120
View directory record Official record
Conditions
Chronic Heart Failure With Reduced Ejection Fraction
Interventions
LCZ696
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
1,980 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
24
States / cities
Huntsville, Alabama • Muscle Shoals, Alabama • Little Rock, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Oct 18, 2026, 5:34 AM EDT
Recruiting Phase 2 Interventional

Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis/Acute Pancreatitis Associated Diabetes Mellitus

NCT06729996
View directory record Official record
Conditions
Pancreatitis, Chronic, Pancreatitis, Acute, Diabetes Mellitus
Interventions
Pioglitazone (PIO), Empagliflozin (EMPA)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Rochester, Minnesota • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 18, 2026, 5:34 AM EDT
Terminated Not applicable Interventional

A Study of the Effects of Eplerenone and Amlodipine on Blood Pressure and Basal Metabolic Rate in Obese Hypertensives

NCT00825188
View directory record Official record
Conditions
Obesity, Hypertension
Interventions
eplerenone, amlodipine, eplerenone, amlodipine
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
21 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Oct 18, 2026, 5:34 AM EDT
Not listed No phase listed Observational

Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF

NCT05865197
View directory record Official record
Conditions
CHF, Congestive Heart Failure
Interventions
Data collection
Other
Lead sponsor
Sensorum Health Inc.
Industry
Eligibility
55 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Oct 18, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines

NCT00232180
View directory record Official record
Conditions
Heart Failure
Interventions
Eplerenone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
55 Years and older
Enrollment
2,743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
51
States / cities
Phoenix, Arizona • Loma Linda, California • Merced, California + 37 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 18, 2026, 5:34 AM EDT
Recruiting Early Phase 1 Interventional

Cardiac Power Output in Cardiogenic Shock Patients

NCT05700617
View directory record Official record
Conditions
Heart Failure, Cardiogenic Shock
Interventions
1:1 Randomization to receive milrinone
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 18, 2026, 5:34 AM EDT
Completed No phase listed Observational

Genetic and Environmental Determinants That Control Metabolism in Pulmonary Hypertension

NCT02594917
View directory record Official record
Conditions
Iron-sulfur Cluster Deficiency, Pulmonary Hypertension, Friedreich Ataxia
Interventions
Right Heart Catheterization, Blood draw
Procedure · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Oct 18, 2026, 5:34 AM EDT
Completed Not applicable Interventional

IMAGE-HF Project I-A: Cardiac Imaging in Ischemic Heart Failure (AIMI-HF)

NCT01288560
View directory record Official record
Conditions
Heart Failure, Coronary Artery Disease, Ischemic Cardiomyopathy
Interventions
Advanced cardiac imaging, Standard Cardiac Imaging
Other
Lead sponsor
Ottawa Heart Institute Research Corporation
Other
Eligibility
18 Years and older
Enrollment
1,390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 18, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients

NCT01922089
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
LCZ696
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
22
States / cities
Anchorage, Alaska • Gilbert, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Oct 18, 2026, 5:34 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Ponsegromab in People With Heart Failure

NCT05492500
View directory record Official record
Conditions
Heart Failure
Interventions
Main cohort (Cohort A): Ponsegromab low dose, Main cohort (Cohort A): Ponsegromab medium dose, Main cohort (Cohort A): ponsegromab high dose, Main cohort (Cohort A): Matched placebo, Open-label, PK Cohort (Cohort B): ponsegromab low dose, Open-label, PK Cohort (Cohort B): ponsegromab medium dose, Open-label, PK Cohort (Cohort B): ponsegromab high dose, Optional Cohort C: Ponsegromab low dose, Optional Cohort C: Matched placebo, Optional Cohort D: Ponsegromab high dose, Optional Cohort D: Matched placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
22
States / cities
Fairhope, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 18, 2026, 5:34 AM EDT
Terminated Not applicable Interventional

Clinical Trial to Evaluate the the ReliantHeart HeartAssist 5® VAD System in Patients Awaiting Heart Transplantation

NCT02205411
View directory record Official record
Conditions
Heart Failure, Cardiac Failure, Congestive Heart Failure, Heart Failure, Left-sided
Interventions
HeartAssist 5® VAD System, Control VAD
Device
Lead sponsor
ReliantHeart Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
14
States / cities
San Francisco, California • Stanford, California • Coral Gables, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 18, 2026, 5:34 AM EDT
Recruiting No phase listed Observational

Tezspire Cardiac Events PASS

NCT06951867
View directory record Official record
Conditions
Cardiovascular Events, MACE
Interventions
Tezepelumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
16,640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 18, 2026, 5:34 AM EDT
Completed Phase 4 Interventional Results available

Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients

NCT05562063
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Juan Badimon
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 18, 2026, 5:34 AM EDT